The Barrel Vascular Reconstruction device (Medtronic) is one of the newest offerings for the treatment of intracranial bifurcation aneurysms. Since receiving the CE mark in January of 2014, the device has been used throughout Europe. Now, Tufail Patankar (Consultant Interventional Neuroradiologist, Leeds Teaching Hospitals NHS Trust, Leeds, UK) speaks to NeuroNews about his experience with the Barrel vascular reconstruction device in his own practice, and explains why there is almost no learning curve associated with its use.
During a presentation at the European Society of Minimally Invasive Neurological Therapy annual meeting (ESMINT; 10–12 September, Nice, France) Jens Fiehler (director of the Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany) said that with the changes made to visibility and vessel wall apposition from Enterprise to Enterprise 2 (Codman Neuro), the problems with the older generation device have been solved.
Decreases in the benefits of intra-arterial clot-busting treatment, as well as a reduced chance for a good outcome, have been associated with delays in restoring blood flow after a stroke, according to an article published online by JAMA Neurology.
The world’s first Clot Summit has been held in Heidelberg, Germany. The meeting was chaired by Werner Hacke, a senior professor of Neurology at the University of Heidelberg Medical School.
InspireMD has received a DEKRA medical device certification for the manufacture and commercialisation of its CGuard delivery catheter.
The European Diagnostics Manufacturers Association (EDMA) and the European Medical Technology Industry (Eucomed) have approved a new joint code of conduct that stipulates that, after 31 December 2017, industry should no longer provide direct “financial or in kind support” to individual healthcare professionals to cover the costs of them attending third-party medical conferences. However, the new code does say that industry can provide educational grants to healthcare organisations to enable them to pay for physicians to attend conferences.
A study published in Circulation has shown adults with congenital heart defects to have much higher rates of stroke, compared to the general population.
Thomas Liebig (Berlin, Germany) reported that a first-line aspiration approach with MicroVention’s Sofia (soft torqueable catheter optimised for intracranial access) device is “worth a try” because it is associated with similar results to first-line aspiration approaches with other dedicated intermediate catheters, and unsuccessful aspiration with Sofia can be “easily converted” into stent retriever-based therapy.
In the Journal of NeuroInterventional Surgery (JNIS), Tufail Patankar (Department of Neuroradiology, Leeds Teaching Hospital, Leeds, UK) and colleagues present the first clinical report on the use of the Comaneci device (Rapid Medical) for the treatment of cerebral aneurysms. In the three-case experience, the investigators found that the Comaneci device can be used to achieve good cerebral aneurysm occlusion, while providing similar benefits to balloon remodelling but alleviating the associated time constraints.
The US FDA (Food and Drug Administration) has issued a safety communication concerning the separation of lubricious coatings from intravascular medical devices. The message aims to make healthcare providers aware of the possibility that hydrophilic and/or hydrophobic coatings may separate from medical devices and cause serious injuries to patients.
The Monarch eTNS system has been granted CE mark approval as a treatment for treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older. According to NeuroSigma, this is the first CE mark approval for a non-drug treatment of ADHD in the European Union.
The Data Safety and Monitoring Board has conducted its second pre-planned safety review of the phase 2 clinical trial of NurOwn in amyotrophic lateral sclerosis, according to a press release from BrainStorm. This randomised, double-blind, placebo-controlled phase 2 clinical trial is being conducted at three US academic medical centres.
Neuravi has announced that the Tennessee Interventional and Imaging Associates at Erlanger Medical Center in Chattanooga, USA, have treated the first patient in an international clinical trial assessing safety and effectiveness of the EmboTrap Revascularisation Device, a novel stent retriever for the treatment of acute ischaemic stroke. Data from the pivotal study, called ARISE II (Analysis of revascularization in ischemic stroke with EmboTrap), will be submitted as part of an application to US Food and Drug Administration (FDA) for approval for the device.
A meta-analysis published in the Journal of the American Medical Association (JAMA) has found that endovascular intervention compared to standard medical care can be associated with improved functional outcomes and higher rates of functional independence at 90 days.
The first patient has been enrolled in the US ROADSTER 2 post approval study at Greenville Memorial Hospital in Greenville, USA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos